b'Driven to Finance Breakthroughs for PatientsRESILIENT GROWTH IN CHALLENGING TIMES2025 UPDATE Despite venture capital pressures and uncertainty in federal funding, our ecosystem delivered results: pre-seed and seed financings that launched new ideas, Series A, B, and C rounds that advanced pipelines, public offerings that surpassed $100 million, and mergers and acquisitions that expanded opportunities. Some highlights are below:$2.1M$32M$15M $10M$100M$300M$230M Cime TherapeuticsFrontera HealthRheumaGen Transverse MedicalUmoja BiopharmaEnvedaEnliven Therapeutics Pre-Seed Seed Series A Series B2 Series C Series C and D Underwritten Public Offering2024 MOMENTUM$2.15B RECENT YEARS OF FUNDRAISING:Colorados life sciences community demonstrated its strength in 2024,Raised in 2024 2021: $2.4B2022: $1.6B2023: $1.47Braising $2.15 billion in capital. This marks the second time in four years$818.5Mthat our ecosystem has surpassed thePublic Capital$2 billion milestone, reinforcing investor confidence in Colorado as the Hub for$445MHealth Impact. Mergers, Acquisitions + PartnershipsSince 2017, Colorados life sciences sector has raised nearly $12 billion,$496.6Mfueling discovery, commercialization,Federal Fundingand growth. The results speak for themselves: our community is driven, resilient, and committed to advancing$383Mscience that transforms lives. Private Capital50 BIOSCIENCE COLORADO 2025-2026'